|Bid||10.87 x 1800|
|Ask||10.77 x 1000|
|Day's Range||9.63 - 13.20|
|52 Week Range||2.50 - 23.66|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.90|
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions. In connection with the investment, the Company agreed to sell 3,846,153 shares of its common stock at a per share price of $6.50, for gross proceeds of approximately $25.0 million.